Sglt2 Inhibitor
SGLT2s, GLP-1s benefit both sexes despite greater CV risks among women with diabetes
The increased risks for cardiovascular disease conferred by diabetes are greater for women than for men, but the newer diabetes drug classes reduce those risks similarly for both sexes, according to a speaker.
DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19
SGLT2 inhibitors could potentially target key mechanisms activated in COVID-19, increasing lipolysis, reducing glycolysis, inflammation and oxidative stress, and improving endothelial function to reduce organ damage, according to a speaker.
SGLT2 inhibitors ‘changed the landscape’ in HF irrespective of diabetes status
SGLT2 inhibitors reduce HF in patients with atherosclerotic CVD or risk factors regardless of diabetes status, but more data are needed particularly in HF with preserved ejection fraction, according to a speaker.
ACC: Cardiologists can use novel therapies to lower CV risk in type 2 diabetes
Cardiologists can use SGLT2 inhibitors and GLP-1 receptor agonists to help reduce risk for major adverse CV events in patients with type 2 diabetes, according to an expert consensus decision pathway from the American College of Cardiology.
SGLT2 inhibitor may cause statin toxicity
Canagliflozin, an SGLT2 inhibitor, may lead to rosuvastatin toxicity when they are prescribed together, according to a case report published in the Annals of Internal Medicine.
Dapagliflozin slows renal disease, reduces death risk regardless of diabetes status
The SGLT2 inhibitor dapagliflozin was linked to significant reductions in worsening renal function and renal or cardiovascular death in adults with chronic kidney disease irrespective of type 2 diabetes, according to a press release.
SGLT2 inhibitors triple DKA risk compared with DPP-IV inhibitors
SGLT2 inhibitor use is associated with an almost threefold increased risk for diabetic ketoacidosis compared with use of DPP-IV inhibitors, according to findings published in Annals of Internal Medicine.
Dapagliflozin remains safe, effective for HF irrespective of diuretic use
Dapagliflozin for worsening HF was both safe and efficacious regardless of diuretic use or dose, according to findings from the DAPA-HF trial published in Circulation.
Success of diabetes treatments varies by cardiovascular risk
Patients with diabetes and increased CVD risk who also received one of several diabetes treatments were more likely to have certain “favorable” health outcomes, researchers reported.
EMPRISE: Empagliflozin demonstrates CV safety, efficacy in real-world population
Two interim analyses of the EMPRISE study supported the effectiveness and CV safety of the SGLT2 inhibitor empagliflozin in real-world patients compared with DPP-IV inhibitors and GLP-1 receptor agonists.